labile toxin mutant ltk63
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00369031)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Escherichia coliImmunity, active
Escherichia coli immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- labile toxin mutant ltk63
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00369031 | Phase 1 | Sep 1, 2006 | European Union, Novartis, Richmond Pharmacology, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Union | Government | 1 | 0 | 1 | 2006 |
| Novartis | For profit | 1 | 0 | 1 | 2006 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2006 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2006 |
4 organizations
Page 1 / 1